InvestLog
BHVN Biohaven Ltd. logo

BHVN Biohaven Ltd.

Healthcare
$9.45-0.32%ClosedMarket Cap: $1.00B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

10.77

P/S

0.00

EV/EBITDA

-1.54

DCF Value

$-0.55

FCF Yield

-59.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-866.5%

ROA

-138.9%

ROIC

-157.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-130.5M$—
Q4 null$0.00$-145.6M$—
FY null$0.00$-738.8M$—
Q3 null$0.00$-173.4M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$16.50

Target (Median)

$16.50

Target Range

$10.00 - $23.00

4 Strong Buy10 Buy5 Hold0 Sell0 Strong Sell
Morgan StanleyOverweight
2026-05-13
RBC CapitalOutperform
2026-05-05
CitigroupBuy
2026-04-02
TD CowenBuy
2026-03-11
HC Wainwright & Co.Neutral
2026-03-04

Trading Activity

Insider Trades

View All
Mehta Kishandirector
SellThu Apr 30
HUGIN ROBERT Jdirector
SellThu Apr 30
Heffernan Michael Thomasdirector
SellThu Apr 30
GREGORY JULIA Pdirector
SellThu Apr 30
CHILDS JOHN Wdirector
SellThu Apr 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

3.31

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Peers

ABCL logoABCLCLDX logoCLDXIMCR logoIMCRIMNM logoIMNMNTLA logoNTLAPHVS logoPHVSSION logoSIONVERA logoVERAXERS logoXERSZBIO logoZBIO